Alkermes (ALKS) Total Debt (2011 - 2026)

Alkermes (ALKS) posted quarterly Total Debt of $1.5 billion for Q2 2026, little changed quarter-over-quarter from $1.5 billion in Q1 2026.

Alkermes (ALKS) Total Debt (2011 - 2026) Analysis & Trends

Alkermes (ALKS) has reported Total Debt for 15 consecutive years, with $1.5 billion the latest figure, recorded in Q2 2026.

In Q2 2026, Total Debt changed N/A year-over-year to $1.5 billion; the TTM figure through Jun 2026 stood at $1.5 billion (changed N/A YoY), while the FY2023 annual figure was $290.7 million, down 0.87% from the prior year.
Total Debt steadied at $1.5 billion in Q2 2026 per ALKS's latest filing, from $1.5 billion in the prior quarter.
Across five years, Total Debt topped out at $1.5 billion in Q1 2026 and bottomed at $288.8 million in Q3 2024.
Historically, Total Debt has averaged $478.9 million across 4 years, with a median of $292.6 million in 2023.
Annual changes were most pronounced in 2022 — Total Debt dropped 0.85% — and 2024, when it retreated 0.87%.
Alkermes' Total Debt stood at $293.3 million in 2022, then retreated by 0.87% to $290.7 million in 2023, then dropped by 0.66% to $288.8 million in 2024, then soared by 420.43% to $1.5 billion in 2026.
Business Quant data shows ALKS's Total Debt at $1.5 billion in Q2 2026, $1.5 billion in Q1 2026, and $288.8 million in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-	-5.81 Bn
2	Teva Pharmaceutical Industries	43.07 Bn	39.42 Bn	2.15 Bn	16.59 Bn
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	9.05 Bn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	31.47 Bn
5	United Therapeutics	22.19 Bn	19.53 Bn	683.80 Mn	-
6	Viatris	18.68 Bn	17.79 Bn	1.46 Bn	13.35 Bn
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn	-
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	3.92 Bn
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	760.00 Mn
10	Alkermes	8.12 Bn	7.46 Bn	397.90 Mn	1.50 Bn

Download Data